There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report), OmniAb (OABI – Research Report) and Vericel (VCEL – Research Report) with bullish sentiments.
Viridian Therapeutics (VRDN)
Leerink Partners analyst Thomas Smith maintained a Buy rating on Viridian Therapeutics on March 20. The company’s shares closed last Friday at $18.01.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $36.82, implying a 97.0% upside from current levels. In a report issued on March 20, Needham also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
OmniAb (OABI)
In a report issued on March 20, Puneet Souda from Leerink Partners maintained a Buy rating on OmniAb, with a price target of $11.00. The company’s shares closed last Friday at $5.13.
According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OmniAb with a $9.71 average price target, representing an 88.9% upside. In a report issued on March 21, Stifel Nicolaus also maintained a Buy rating on the stock with a $11.00 price target.
Vericel (VCEL)
Leerink Partners analyst Mike Kratky reiterated a Buy rating on Vericel on March 21 and set a price target of $51.00. The company’s shares closed last Friday at $46.90, close to its 52-week high of $50.09.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vericel with a $51.68 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRDN:
- Viridian Therapeutics price target lowered to $25 from $29 at B. Riley
- Viridian Therapeutics, Inc. (VRDN) Q4 Earnings Cheat Sheet
- Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo
- Viridian Therapeutics price target raised to $40 from $39 at Wedbush
- Viridian Therapeutics price target lowered to $37 from $38 at JMP Securities
